Tanox to Acquire Assets From Sunol

Tanox has inked a deal with Miramar, Fla.-based Sunol Molecular Corp. to acquire Sunol's tissue factor antagonist program for $6 million and Tanox stock shares. Under terms of the agreement, Tanox will receive all tissue factor antagonist assets from the biopharmaceutical company, including anti-tissue factor monoclonal antibodies and related technologies and intellectual properties, as well as nonexclusive rights to certain technologies and related intellectual property for protein and antibody expression.

Houston Business Journal (http://www.bizjournals.com/houston/stories/2005/03/28/daily2.html)